What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Filgotinib demonstrated moderate benefit over placebo in the SELECTION trial, with statistically significant higher rates of endoscopic remission in both biologic-naive and biologic-experienced participants. However, the lack of direct head-to-head evidence against standard treatments limits the strength of the claim for superiority.
Does the economic case hold at the expected price? — Cost effectiveness
The cost-effectiveness estimates for filgotinib are within the range that NICE considers acceptable, particularly when accounting for the commercial arrangement that provides a discount. This suggests a defensible economic value despite some uncertainties.
Is there quality-of-life evidence payers weigh? — Quality of life
The evidence suggests moderate improvements in HRQoL for patients treated with filgotinib, as indicated by the clinical experts’ discussions on the impact of ulcerative colitis on daily life. However, specific validated HRQoL data were not extensively detailed in the document.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Filgotinib has a good safety profile with mostly mild to moderate adverse events reported. The committee expressed concerns about potential cardiovascular risks, but overall, the adverse effects were manageable and comparable to existing therapies.
Was the drug compared against what payers expect? — Comparator Selection
The document indicates that while filgotinib was compared to placebo, the lack of direct comparisons with standard treatments like TNF-alpha inhibitors limits the robustness of the evidence. The committee noted that conventional treatment is not an appropriate comparator for filgotinib.
Is the population defined the way payers need it? — Patient Population and Subgroups
The SELECTION trial included a diverse population of adults with moderately to severely active ulcerative colitis, and the committee noted that the trial population is broadly generalizable to the intended patient population in clinical practice.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Filgotinib can be integrated into existing treatment pathways with minor adjustments, as it is an oral treatment option that may be more convenient for patients compared to other therapies that require injections or infusions.
Are the wider system costs understood? — Resource Use and Cost Implications
The economic model suggests that filgotinib has a manageable budget impact, especially with the commercial arrangement in place. The committee acknowledged that the cost implications are justifiable given the potential benefits.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence from the SELECTION trial is robust, being a phase 2b/3 RCT with a well-defined methodology. However, the reliance on indirect comparisons for efficacy against standard treatments introduces some uncertainty.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the long-term effectiveness of filgotinib, particularly in the maintenance phase, and the committee expressed concerns about the assumptions made in the economic model. These uncertainties could impact broader decision-making.
